 CAMBRIDGE, Mass., April 19, 2021 GLOBE NEWSWIRE -- Checkmate Pharmaceuticals Inc. NASDAQ: CMPI Checkmate, a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the initiation of dosing in a Phase 2 proof-of-concept trial in patients with head and neck squamous cell carcinoma HNSCC. The trial will assess the efficacy and safety of vidutolimod CMP-001 in combination with pembrolizumab for the treatment of patients with first-line relapsed or metastatic HNSCC. The results of this trial are expected in the 2nd half of 2022, with initial data in a subset of patients anticipated before the end of 2021. 